Radium-223 in Prostate Cancer
Authors:
- Chris ParkerCPChris Parker
- Oliver SartorOSOliver Sartor
- 24 October 2013
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (17) , 1659-1660
Abstract
To the Editor: In their editorial on the use of radium-223 for the treatment of bone metastases in prostate cancer, Vapiwala and Glatstein (July 18 issue)1 provide an overview of the benefits of alpha-emitting radioisotopes. They focus on the results reported in the same issue of the Journal by Parker et al.,2 who describe the association between the use of radium-223 dichloride and an observed increase in survival, as compared with placebo. In both the article and the editorial, the authors suggest that current radiopharmaceutical agents for bone pain palliation do not prolong survival, with the editorialists stating that “the . . .Keywords
This publication has 6 references indexed in Scilit:
- Fighting Prostate Cancer with Radium-223 — Not Your Madame's IsotopeNew England Journal of Medicine, 2013
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED.Journal of Clinical Oncology, 2013
- Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective AnalysisJournal of Nuclear Medicine, 2011
- Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 HydroxyethylidenediphosphonateJournal of Clinical Oncology, 2003
- Reactor-produced radioisotopes from ORNL for bone pain palliationApplied Radiation and Isotopes, 1998